| NewYork-Presbyterian
Hospital's Center for Special Studies (CSS) offers the highest quality
multidisciplinary health care available for people with HIV and AIDS.
The center has sites at NewYork-Presbyterian Hospital/Weill Cornell Medical Center and in the
ground floor of Gay Men's Health Crisis (GMHC) building. State of the
art medical care is the centerpiece of our treatment philosophy which
also extends to the psychological, social, and spiritual needs of individuals
and families living with HIV and AIDS. To arrange an appointment at the
Center for Special Studies, please call: |
 |
|
The Glenn
Bernbaum Unit 525
East 68th Street, Room F-24
New York, NY 10021
(212) 746-4180
|
The David
Rogers Unit
119 West 24th Street
New York, NY 10011
(212) 746-7200
|
|
|
CSS
was certified by the New York State Department of Health in 1988 as a
designated AIDS care facility. In addition to outpatient primary care,
CSS provides inpatient services in a newly renovated, 45-bed medical unit
located in the hospital's Greenberg Pavillion. In 1997 CSS opened the
David Rogers unit of the Center for Special Studies in collaboration with
the Gay Men's Health Crisis. The downtown
facility is the first ever large-scale partnership of a major NewYork
academic medical center with a community-based AIDS service organization.
Clients of Rogers unit of CSS have access to the same high quality, comprehensive
primary care for which the center is known, as well as GMHC's spectrum
of services, including crisis intervention, intensive case management,
legal and financial advocacy, nutritional counseling, recreational classes,
treatment and prevention information and counseling, and other social
services. |
|
In
addition to delivering superior health care to patients, New York-Presbyterian
has been at the forefront of AIDS research since the epidemic began. In
1988 the medical center was designated as an AIDS Clinical Trials Unit
by the National Institutes of Health. The Cornell Clinical Trials Unit
(CCTU) located at both sites
is dedicated to providing access to experimental treatments to all HIV-infected
individuals. |